Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to metformin in type 2 diabetes mellitus
2006-001335-22Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: Change in HbA1c at 18 weeks and Safety and tolerability of sitagliptin. Started May 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-001335-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001335-22.